| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 36 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
| 体型 | 肥満 |
この研究の注釈：
In obese type II diabetic (on medication) subjects given supplemental chromium via yeast (400 micrograms daily) for 12 weeks was associated with a decrease in blood glucose relative to placebo but all other measured biomarkers were unchanged, although a reduction in insulin and weight in both groups tended to decrease further with chromium.
In obese type II diabetic (on medication) subjects given supplemental chromium via yeast (400 micrograms daily) for 12 weeks was associated with a decrease in blood glucose relative to placebo but all other measured biomarkers were unchanged, although a reduction in insulin and weight in both groups tended to decrease further with chromium.
Lipid peroxidation (MDA) was unaffected and the antioxidant enzymes were mostly unaffected, although a decrease in glutathoine and glutathione peroxidase seen at the end of the trial in placebo was mitigated with chromium.
The Effects Of Inorganic Chromium And Brewer’s Yeast Supplementation On Glucose Tolerance, Serum Lipids And Drug Dosage In Individuals With Type 2 Diabetes
| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 78 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
| 体型 | 平均 |
この研究の注釈：
Low dose chromium supplementation (23.3mcg) via Brewer’s Yeast and 200mcg chromium as trichloride for eight weeks in type II diabetics both appeared to reduce both fasting and postprandial blood glucose (75g glucose tolerance test) and was able to reduce fructosamine as well.